Drugs / AMG 424
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | plasma cell myeloma | 2017-12-05 | “The payment is triggered by the submission of the Investigational New Drug (IND) Application for AMG 424” xencor.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03445663 | Jul 2018 → Jun 2020 | refractory plasma cell neoplasm | Xencor, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-12-05 | Xencor, Inc. | Regulatory Xencor Receives Milestone Payment from Amgen xencor.com ↗
The payment is triggered by the submission of the Investigational New Drug (IND) Application for AMG 424, a novel humanized T cell-recruiting bispecific antibody targeting CD38 and CD3, which uses Xencor's Bispecific XmAb® Technology. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-12-05 | Xencor, Inc. | Xencor Receives Milestone Payment from Amgen xencor.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 424 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03445663 ↗ |
| Route | Intravenous | “Subjects will receive IV infusions of AMG 424” NCT03445663 ↗ |